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Introduction
============

Transfusion of red blood cells are often used to treat anaemia or bleeding in a variety of patient groups.[@ref1] [@ref2] [@ref3] Recent results of randomised clinical trials[@ref4] [@ref5] [@ref6] [@ref7] [@ref8] have favoured restrictive transfusion strategies and elucidated potential harm with liberal transfusion strategies. Data from several newly published randomised controlled trials[@ref9] [@ref10] [@ref11] [@ref12] [@ref13] warrant an up to date review of the available evidence comparing the effects of different transfusion thresholds to inform on the benefits and harms of transfusion strategies guiding red blood cell transfusion. A Cochrane review identified 19 randomised controlled trials including 6264 patients.[@ref14] Most of the data on mortality were from the Transfusion Requirements in Critical Care (TRICC) trial[@ref4] (52%) and Transfusion Trigger Trial for Functional Outcomes in Cardiovascular Patients Undergoing Surgical Hip Fracture Repair (FOCUS) trial (23%),[@ref15] underlining the somewhat limited evidence base for guiding the use of red blood cells.[@ref16]

We carried out a systematic review including data from the latest published randomised controlled trials and used conventional meta-analysis to compare the effects of different transfusion strategies on important outcomes in various patient groups. We were particularly interested to examine whether the evidence supported a restrictive strategy without harm to patients.

Methods
=======

Our systematic review was conducted according to the protocol previously published in the PROSPERO register ([www.crd.york.ac.uk/PROSPERO](http://www.crd.york.ac.uk/PROSPERO)). The methodology and reporting were based on recommendations from the Cochrane Collaboration[@ref17] and the preferred reporting items for systematic reviews and meta-analyses statement,[@ref18] and evaluated according to the GRADE (grading of recommendations assessment, development, and evaluation) guidelines.[@ref19]

Eligibility criteria
--------------------

We considered prospective randomised controlled trials to be eligible for inclusion if red blood cell transfusions were administered on the basis of a clear transfusion "trigger" or "threshold," defined as a specific haemoglobin or haematocrit level. Comparator group patients were required to be either transfused at higher haemoglobin or haematocrit levels than the intervention group or transfused in accordance with current transfusion practices. We considered for inclusion trials that included surgical or medical patients and adults or children, but excluded trials conducted on neonates and children with low birth weight.

All randomised controlled trials were eligible irrespective of language, blinding, publication status or date, or sample size. We excluded quasirandomised trials for assessment of benefit but considered them for inclusion for assessment of harm.

Search strategy
---------------

We identified relevant randomised controlled trials through an up to date systematic search strategy used in a published Cochrane review[@ref14]; in the Cochrane central register of controlled trials, SilverPlatter Medline (1950 to October 2014), SilverPlatter Embase (1980 to October 2014), and Science Citation Index Expanded (1900 to October 2014). To identify any planned, unreported, or ongoing trials we contacted the main authors of included trials and experts in this discipline. We reviewed the references of included trials to identify additional trials. Moreover, we identified ongoing clinical trials and unpublished trials through Current Controlled Trials, ClinicalTrials.gov, and [www.centerwatch.com](http://www.centerwatch.com/) (see supplementary appendix 1 for detailed information on the search strategy).

Trial selection
---------------

Authors (LB, MWP, and NH) independently reviewed all titles and abstracts identified through the systematic search. They excluded trials that did not fulfil the eligibility criteria and evaluated the remaining trials in full text. Disagreements were resolved with JW.

Data extraction
---------------

The researchers were not masked to the author, institution, and publication source of trials at any time. Using preprepared extraction forms the researchers (LBH, NH, or MWP) independently extracted the characteristics of the trials (single or multicentre, country), baseline characteristics of the patients (age, sex, disease severity), inclusion and exclusion criteria, the description of intervention (thresholds, duration), and outcomes. When information was unclear or missing we contacted the corresponding authors of the relevant trials.

Predefined primary outcomes were mortality and overall morbidity, defined by authors as one or more complications, overall complications, or any adverse event (if not reported, we included the most common complication). Secondary outcomes were adverse events (transfusion reactions, cardiac events---for example, myocardial infarction, cardiac arrest, acute arrhythmia, angina), renal failure, thromboembolic events, infections, haemorrhagic events, stroke, or transitory cerebral ischaemia. We also registered the proportion of patients transfused with allogeneic or autologous red blood cells, and the number of allogeneic and autologous blood units transfused. Haemoglobin or haematocrit levels during intervention and length of hospital stay were regarded as process variables and thus reported as trial characteristics.

Risk of bias assessment
-----------------------

According to recommendations from the Cochrane Collaboration[@ref17] we reviewed the major domains of bias (random sequence generation, allocation concealment, blinding of participants and staff, blinding of outcome assessors, incomplete outcome data, selective outcome reporting, baseline imbalance, sponsor bias (bias related to funding source), and academic (whether authors had published other trials in the same field of research) in all trials. We categorised trials with low risk of bias as those with a lower risk of bias in all domains except blinding because blinding of trigger guided transfusion is generally not feasible. All other trials were categorised as unclear or at high risk of bias.

Grading quality of evidence
---------------------------

We assessed the quality of evidence for mortality, overall morbidity, and fatal and non-fatal myocardial infarction according to GRADE methodology[@ref19] for risk of bias, inconsistency, indirectness, imprecision, and publication bias; classified as very low, low, moderate, or high.

Statistical analysis
--------------------

All statistical analyses were performed using Review Manager (RevMan) version 5.3.3 (Nordic Cochrane Centre, Cochrane Collaboration) and trial sequential analysis program version 0.9 beta ([www.ctu.dk/tsa](http://www.ctu.dk/tsa)).[@ref20] For all included trials we report relative risks (95% confidence intervals) for dichotomous outcomes and mean differences (95% confidence intervals) for continuous outcomes. We pooled these measures in meta-analyses.

If data from two or more trials were included in analysis of an outcome, we used random effects[@ref20] and fixed effect models[@ref21] for meta-analyses. We report the results from both models if there was discrepancy between the two; otherwise we report results from the random effects model. Heterogeneity among trials was quantified with inconsistency factor (I^2^) or (D^2^) statistics[@ref22] and by χ^2^ test, with significance set at a P value of 0.10. We did sensitivity analyses by applying continuity adjustment in trials with zero events.[@ref17]

For risk of bias we performed predefined subgroup analyses (lower versus high or unclear risk) and we emphasise the results from the trials with lower risk of bias,[@ref17] patient populations (adults versus children; surgical versus medical), length of follow-up (≤90 days versus \>90 days), and transfusion product (leucocyte reduced versus non-leucocyte reduced red blood cell suspensions). Only subgroup analyses showing a statistically significant test of interaction (P\<0.05) were considered to provide evidence of an intervention effect. We preplanned exploration of moderate to high heterogeneity using metaregression, including mean age and fraction of men as covariates if possible. However this was not feasible owing to missing values of the covariates in the included trials, but we performed a post hoc subgroup analysis, stratifying trials according to clinical setting. There were no data to support the predefined subgroup analysis of randomised trials of patients with sepsis compared with patients without sepsis.

Meta-analyses may result in type I errors owing to an increased risk of random error when sparse data are analysed[@ref23] and due to repeated significance testing when a cumulative meta-analysis is updated with new trials.[@ref20] [@ref24] To assess the risk of type I errors we applied trial sequential analysis to cumulative meta-analysis. Trial sequential analysis combines an estimation of information size (cumulated sample size of included trials) with an adjusted threshold for statistical significance[@ref20] [@ref25] in the cumulative meta-analyses.[@ref26] The latter, termed trial sequential monitoring boundaries, adjusts the confidence intervals and reduces type I errors. When the cumulative z curve crosses the trial sequential monitoring boundary, a sufficient level of evidence for the anticipated intervention effect may have been reached and no further trials are needed. If the z curve does not cross any of the boundaries and the required information size has not been reached, evidence to reach a conclusion is insufficient. We calculated information size as a diversity adjusted required information size,[@ref27] suggested by the diversity of the intervention effect estimates among the included trials.

The required information size was calculated based on a relative risk reduction of 15% in mortality and overall morbidity and a relative risk reduction of 50% in myocardial infarction. We appropriately adjusted all trial sequential analyses for heterogeneity (diversity adjustment) according to an overall type I error of 5% and a power of 80%, considering early and repetitive testing.

Results
=======

Trial selection
---------------

In the updated systematic search strategy we identified an additional 1930 records, of which 38 were assessed in full text for eligibility to supplement the former 19 published randomised controlled trials. In total we found 33 eligible records published, all in English, between October 1986 and October 2014, describing 31 trials of 9813 patients.[@ref4] [@ref5] [@ref6] [@ref7] [@ref8] [@ref9] [@ref10] [@ref11] [@ref12] [@ref13] [@ref15] [@ref28] [@ref29] [@ref30] [@ref31] [@ref32] [@ref33] [@ref34] [@ref35] [@ref36] [@ref37] [@ref38] [@ref39] [@ref40] [@ref41] [@ref42] [@ref43] [@ref44] [@ref45] [@ref72] [@ref73] Three identified records provided data from the same trial.[@ref45] [@ref46] [@ref47] We excluded a total of 26 records,[@ref46] [@ref47] [@ref48] [@ref49] [@ref50] [@ref51] [@ref52] [@ref53] [@ref54] [@ref55] [@ref56] [@ref57] [@ref58] [@ref59] [@ref60] [@ref61] [@ref62] [@ref63] [@ref64] [@ref65] [@ref66] [@ref67] [@ref68] [@ref69] [@ref70] [@ref71] the primary reasons being a lack of well defined haemoglobin or haematocrit levels guiding the intervention (six records),[@ref48] [@ref49] [@ref50] [@ref51] [@ref52] [@ref53] the inclusion of preterm or very low birth weight neonates (seven records),[@ref54] [@ref55] [@ref56] [@ref57] [@ref58] [@ref59] [@ref60] [@ref71] and secondary publications or subgroup analyses (nine records).[@ref46] [@ref47] [@ref60] [@ref61] [@ref62] [@ref63] [@ref64] [@ref65] [@ref66] Three records related to ongoing trials.[@ref67] [@ref68] [@ref69] Figure 1[](#fig1){ref-type="fig"} summarises the results of the search strategy.

![**Fig 1** Flow of trials through study](holl023030.f1_default){#fig1}

Characteristics of trials
-------------------------

We included both single (17 trials)[@ref6] [@ref7] [@ref11] [@ref12] [@ref28] [@ref29] [@ref30] [@ref31] [@ref33] [@ref34] [@ref35] [@ref38] [@ref39] [@ref41] [@ref42] [@ref43] [@ref72] and multicentre (14 trials)[@ref4] [@ref5] [@ref8] [@ref9] [@ref10] [@ref13] [@ref15] [@ref32] [@ref36] [@ref37] [@ref40] [@ref44] [@ref45] [@ref73] randomised controlled trials. Population sizes ranged from 25[@ref34] to 2016,[@ref15] and eight trials included more than 500 patients.[@ref4] [@ref5] [@ref6] [@ref7] [@ref9] [@ref13] [@ref15] [@ref45] The clinical settings of most of the randomised controlled trials were perioperative and acute blood loss (20 trials),[@ref6] [@ref7] [@ref11] [@ref12] [@ref13] [@ref15] [@ref30] [@ref31] [@ref32] [@ref33] [@ref34] [@ref35] [@ref36] [@ref38] [@ref39] [@ref41] [@ref42] [@ref45] [@ref72] critical care (eight trials),[@ref4] [@ref5] [@ref8] [@ref9] [@ref10] [@ref37] [@ref40] [@ref73] and trauma (two trials),[@ref29] [@ref43] and one trial included patients with leukaemia undergoing stem cell transplantation.[@ref44] Table 1[](#tbl1){ref-type="table"} summarises the characteristics of the included trials.

###### 

 Characteristics of included trials

  Reference                 Source                                             Country                 No of patients/No of trial sites   Inclusion period    Clinical setting                                                                               RBCs (type/suspension/leucocyte reduced)            Storage age^\*^                  Protocol violations†                                          Intervention trigger value‡
  ------------------------- -------------------------------------------------- ----------------------- ---------------------------------- ------------------- ---------------------------------------------------------------------------------------------- --------------------------------------------------- -------------------------------- ------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------
  Almeida 2013^11^          *Critical Care*                                    Brazil                  198/1                              Jan 2012-Dec 2012   Patients with cancer undergoing major abdominal surgery requiring postoperative ICU care       NA/NA/NA                                            NA                               NA                                                            R: 7, L: 9
  Blair 1986^29^            *Brirish Journal of Surgery*                       UK                      50/1                               NA                  Surgical patients with gastrointestinal bleeding                                               Allogen/citrate/NA                                  NA                               NA                                                            R: 8 or persistent shock, L: 2 units
  Bracey 1999^31^           *Transfusion*                                      USA                     428/1                              Feb 1997-Nov 1997   First time elective CABG surgery                                                               Allogen/NA/NA                                       NA                               NA                                                            R: 8 or predefined clinical condition, L: 9
  Bush 1997^30^             *American Journal of Surgery*                      USA                     99/1                               Aug 1995-Nov 1996   Elective aortic or infrainguinal arterial reconstruction                                       Allogen/NA/NA                                       NA                               R: 3, L: 2                                                    R: 9, L: 10
  Carson 1998^32^           *Transfusion*                                      USA/Scotland            84/4                               Mar 1996-Mar 1997   Patients with primary hip fracture                                                             Allogen/NA/NA                                       NA                               R: 4/42, L: 1/42                                              R: 8 or symptoms of anaemia, L: 10
  Carson 2011^15^           *New England Journal of Medicine*                  USA/Canada              2016/47                            May 2003-Oct 2009   Primary with hip fracture and CVD or risk of CVD                                               Allogen/NA/leucocyte reduced (R: 88.6%, L: 90.2%)   R: 22.1 (9.9), L: 22.0 (9.5)     R: 56/1007, L: 91/1006                                        R: 8 or symptoms of anaemia, L: 10
  Carson 201^38^            *American Heart Journal*                           USA                     110/8                              Mar 2010-May 2012   Patients with coronary syndrome or stable coronary artery disease undergoing catheterisation   Allogen/NA/leucocyte reduced (R: 92%, L: 95%)       R: 24.6 (9.1), L: 23.4 (10.9)    R: 1/55, L: 5/55                                              R: 8 or symptoms of anaemia, L: 10
  Cholette 2011^33^         *Pediatric Critical Care*                          USA                     60/1                               Aug 2006-Sep 2009   Infants and children with single ventricle physiology undergoing cavapulmonary bypass          Allogen/NA/leucocyte reduced                        NA                               R: 0/30, L: 0/30                                              R: 9 with symptoms, L: 13
  Cooper 2011^71^           *American Journal of Cardiology*                   USA                     45/2                               May 2003-Oct 2009   Acute myocardial infarction                                                                    Allogen/NA/leucocyte reduced                        NA                               NA                                                            R: haematocrit \<24 (24-27)%, L: 30 (30-33)%
  De Gast-Bakker 2013^35^   *Intensive Care Medicine*                          Netherlands             107/1                              Apr 2009-Jan 2012   Infants and children undergoing elective heart surgery for congenital heart defect             Allogen/NA/leucocyte reduced                        R: 9.8 (6.8), L: 9.8 (7.2)       R: 3/53, L: 4/54                                              R: 8.0, L: 10.8
  Gregersen 2013^72^        *European Geriatric Medicine*                      Denmark                 160/1                              NA                  Patients with hip fracture                                                                     NA/NA/NA                                            NA                               NA                                                            R: 9.7, L: 11.3
  Fortune 1987^34^          *Journal of Trauma*                                USA                     25/1                               NA                  Traumatic pts with haemorrhagic shock (class 3-4)                                              Allogen/NA/NA                                       NA                               NA                                                            R: haematocrit \<30%, L: \<40%
  Foss 2009^28^             *Transfusion*                                      Denmark                 120/1                              Feb 2004-Jul 2006   Patients with primary hip fracture                                                             Allogen/NA/leucocyte reduced                        NA                               NA                                                            R: 8.0, L: 10.0
  Grover 2006^36^           *Vox Sanguinis*                                    UK                      260/3                              NA                  Elective total knee or hip arthroplasty                                                        Allogen/NA/leucocyte reduced                        NA                               NA                                                            R: 8 and maintained between 8.0 and 9.5, L: \<10 and maintained between 10.0 and 12.0
  Hajjar 2010^7^            *Journal of the American Medical Association*      Brazil                  502/1                              Feb 2009-Feb 2010   Elective CABG and/or valve replacement                                                         Allogen/citrate/non-leucocyte reduced               NA                               R: 0/255, L: 1/257                                            R: haemoatocrit \<24%, L: \<30%
  Hébert 1995^37^           *Journal of the American Medical Association*      Canada                  69/25                              Mar 1993-Jan 1994   Euvolaemic, critically ill patients                                                            Allogen/NA/non-leucocyte reduced                    NA                               R: 2/33, L: 2/36                                              R: 7, L: 9
  Hebert 1999^4^            *New England Journal of Medicine*                  Canada                  838/25                             Nov 1994-Nov 1997   Euvolaemic, critically ill patients                                                            Allogen/citrate/non-leucocyte reduced               NA                               R: 6/418 (crossover: 4/418), L: 18/420, (crossover: 11/420)   R: 7.0 (7.0-9.0), L: 10.0 (10.0-12.0)
  Holst 2014^9^             *New England Journal of Medicine*                  Scandinavia             1005/32                            Dec 2011-Dec 2013   Septic shock                                                                                   Allogen/SAGM/leucocyte reduced                      NA                               R: 45/463, L: 16/470                                          R: 7, L: 9
  Johnson 1992^38^          *Journal of Thoracic and Cardiovascular Surgery*   USA                     39/1                               NA                  Elective revascularisation                                                                     Allogen and autologous/NA/non-leucocyte reduced     NA                               R: 1/21, L: 0/18                                              R: haematocrit \<25%, L: \<32%
  Lacroix 2007^5^           *New England Journal of Medicine*                  Canada/USA/UK/Belgium   648/19                             Nov 2001-Aug 2005   Stable, critically ill infants and children                                                    Allogen/NA/leucocyte reduced                        R: 16.0 (10.5), L: 15.7 (10.3)   R: 1/320, L: 10/317                                           R: 7 (8.5-9.5), L: 9.5 (11.0-12.0)
  Lotke 1999^39^            *Journal of Arthroplasty*                          USA                     152/1                              NA                  Total knee arthroplasty                                                                        Allogen and autologous/NA/non-leucocyte reduced     NA                               NA                                                            R: 9.0, L: 2 units
  Parker 2013^12^           *Injury*                                           England                 200/1                              NA                  Patients with primary hip fracture                                                             NA/NA/NA                                            NA                               NA                                                            R: symptoms of anaemia,§ L: 10
  Prick 2013^13^            *British Journal of Obstetrics and Gynaecology*    Netherlands             521/37                             May 2004-Feb 2011   Patients with sustained postpartum haemorrhage                                                 Allogen/NA/NA                                       NA                               R: 33, L: 7                                                   R: symptoms of anaemia¶, L: 8.9
  Robertson 2014^40^        *Journal of the American Medical Association*      USA                     200/2                              May 2006-Aug 2012   Patients with closed head injury                                                               NA/NA/leucocyte reduced                             NA                               R: 4/99, L: 0/101                                             R: 7, L: 10
  Shehata 2012^41^          *Transfusion*                                      Canada                  50/1                               Jan 2007-Jun 2010   Patients with elective cardiac surgery                                                         Allogen/NA/NA                                       NA                               R: 16%, L: 59%                                                R: 70 g/L perioperatively and 75 g/L postoperatively, L: 95 g/L perioperatively and 100 g/L postoperatively
  So-Osman 2010^45^         *Vox Sanguinis*                                    Netherlands             619/3                              2001-2003           Primary elective hip or knee replacement                                                       Allogen/NA/leucocyte reduced                        NA                               NA                                                            R: new restrictive transfusion policy related to cardiopulmonary comorbidity, time since surgery, and including centre L: standard of care
  Villanueva 2013^6^        *New England Journal of Medicine*                  Spain                   921/1                              NA                  Patients with upper gastrointestinal bleeding                                                  Allogen/NA/leucocyte reduced                        NA                               R: 39/444, L: 15/445                                          R: 7, L: 9
  Walsh 2013^10^            *Critical Care Medicine*                           England                 100/6                              Aug 2009-Dec 2010   Mechanically ventilated patients in ICU                                                        Allogen/SAGM/leucocyte reduced                      NA                               R: 2/51, L: 3/49                                              R: 7, L: 9
  Webert 2008^44^           *Transfusion*                                      Canada                  60/4                               Mar 2003-Oct 2004   Patients with acute leukaemia undergoing stem cell transplantation                             Allogen/AS-3/leucocyte reduced                      NA                               R: 24/29, L: 28/31                                            R: 80 g/L, L: 120 g/L
  Wu 2011^42^               ESICM 24th annual congress 2011                    China                   226/1                              NA                  Orthotopic liver transplantation                                                               NA/NA/NA                                            NA                               NA                                                            R: 7 (7-9), L: 10 (10-12)
  Zygun 2009^43^            *Neurological Critical Care*                       England                 30/1                               Jan 2003-Jul 2005   Severe traumatic brain injury                                                                  Allogen/NA/NA                                       NA                               NA                                                            R: 8.0 (2 units transfused), L1: 9.0 (2 units transfused), L2: 10.0 (2 units transfused)

RBC=red blood cells; ICU=intensive care unit; NA=not available; R=restrictive; L=liberal; CABG=coronary artery bypass graft; CVD=cardiovascular disease; SAGM=erythrocyte storage in hypertonic conservation medium; ESCIM=European Society of Intensive Care Medicine.

\*Values are mean (standard deviation) days unless otherwise specified.

†Values are proportions of patients unless otherwise specified.

‡Haemoglobin levels are reported in g/dL unless stated otherwise.

§Symptoms of anaemia included recurrent vasovagal episodes on mobilisation, chest pain of cardiac origin, congestive cardiac failure, unexplained tachycardia, hypotension or dyspnoea due to anaemia, decreased urine output unresponsive to fluid replacement, and any other symptoms believed appropriate by the medical staff looking after the patient.

¶Symptoms of anaemia defined as dyspnoea or syncope.

Intervention
------------

In 24 trials,[@ref4] [@ref5] \[8-7\] [@ref9] [@ref10] [@ref12] [@ref13] [@ref28] [@ref30] [@ref31] [@ref32] [@ref33] [@ref34] [@ref35] [@ref36] [@ref37] [@ref40] [@ref41] [@ref43] [@ref44] [@ref45] [@ref73] patients received allogeneic red blood cells, and among these two trials also allowed the use of autologous transfusion.[@ref38] [@ref39] For the remaining five trials there was no information on the type of red blood cells used.[@ref11] [@ref12] [@ref40] [@ref42] [@ref72] Leucocyte reduced red blood cells were transfused in 12 trials,[@ref5] [@ref6] [@ref9] [@ref10] [@ref28] [@ref33] [@ref35] [@ref36] [@ref40] [@ref45] [@ref46] [@ref73] and partially leucocyte reduced red blood cells were administered in two trials.[@ref8] [@ref15] Non-leucocyte reduced red blood cells were used in five trials,[@ref4] [@ref7] [@ref37] [@ref38] [@ref39] and information was not provided for the remaining 12 trials.[@ref11] [@ref12] [@ref13] [@ref29] [@ref30] [@ref31] [@ref32] [@ref34] [@ref42] [@ref43] [@ref72]

The intervention trigger value varied between trials. The triggers for restrictive transfusion ranged from haemoglobin 7.0 to 9.7 g/dL, haematocrit 24% to 30%, or symptoms of anaemia as defined by the authors. The triggers for liberal transfusion ranged from haemoglobin 9 to 13 g/dL and haematocrit 30% to 40%.

Risk of bias assessment
-----------------------

Table 2[](#tbl2){ref-type="table"} provides detailed information on blinding. Overall, 12 randomised controlled trials were categorised as at lower risk of bias,[@ref4] [@ref5] [@ref6] [@ref9] [@ref10] [@ref13] [@ref14] [@ref15] [@ref28] [@ref32] [@ref35] [@ref73] 14 as unclear,[@ref8] [@ref11] [@ref12] [@ref29] [@ref33] [@ref34] [@ref37] [@ref38] [@ref39] [@ref40] [@ref41] [@ref42] [@ref43] [@ref72] and five as at high risk of bias.[@ref7] [@ref30] [@ref31] [@ref36] [@ref45] Figures 2[](#fig2){ref-type="fig"} and 3[](#fig3){ref-type="fig"} summarise the risks of bias.

###### 

 Summary of reported blinding procedure in included trials to supplement ROB table (figure 2.) on blinding procedure, not assessed in overall evaluation of trial bias domains owing to feasibility issues

  Reference                 Patient         Clinical/trial staff                                                                  Outcome assessor
  ------------------------- --------------- ------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Almeida 2013^11^          Not available   Not available                                                                         Not available
  Blair 1986^29^            Not available   Not available                                                                         Not available
  Bracey 1999^31^           Not blinded     Not blinded                                                                           Not blinded
  Bush 1997^30^             Not available   Surgeons/anaesthesiologists not blinded; clinical staff not available                 Not available
  Carson 1998^32^           Not available   Not available                                                                         Study nurses obtaining subjective (functional status, place of residence) and objective outcomes (60 day survival status) were blinded for intervention during follow-up by telephone
  Carson 2011^15^           Not blinded     Not blinded                                                                           Study nurses obtaining subjective (functional status, place of residence) and objective outcomes (60 day survival status) were blinded for intervention during follow-up by telephone
  Carson 2013^8^            Not available   Not available                                                                         Composite outcome of death and myocardial infarction; study nurses obtaining subjective (functional status, place of residence) and objective outcomes (myocardial infarction, unstable angina, 60 day survival status) were blinded for intervention during follow-up by telephone
  Cholette 2011^33^         Not blinded     Operation staff blinded perioperatively; clinical staff not blinded postoperatively   Outcome assessor not available; data and safety monitoring committee blinded
  Cooper 2011^71^           Not blinded     Not blinded                                                                           Not available
  Fortune 1987^34^          Not available   Not available                                                                         Not available
  Foss 2009^28^             Blinded         Not available                                                                         Physiotherapist assessing ambulation blinded
  De Gast-Bakker 2013^35^   Not blinded     Not blinded                                                                           Not blinded
  Gregersen 2013^72^        Not available   Not available                                                                         Not available
  Grover 2006^36^           Blinded         Surgeons/anaesthesiologists not blinded; clinical staff not available                 Holter monitor assessor blinded
  Hajjar 2010^7^            Blinded         Anaesthesiologists/intensive care unit clinicians blinded; surgeons not available     Outcome assessor blinded; data and safety monitoring committee not available
  Hébert 1995^37^           Not blinded     Not blinded                                                                           Not available
  Hébert 1999^4^            Not blinded     Not blinded                                                                           Outcome assessor not available; data and safety monitoring committee blinded
  Holst 2014^9^             Not blinded     Not blinded                                                                           Outcome assessor; statisticians and data and safety monitoring committee blinded
  Johnson 1992^38^          Not available   Surgeons/anaesthesiologists not blinded; clinical staff not available                 Not available
  Lacroix 2007^5^           Not blinded     Not blinded                                                                           Outcome assessor not available; statisticians and data and safety monitoring committee blinded
  Lotke 1999^39^            Not available   Not available                                                                         Blinded
  Parker 2013^12^           Not available   Not available                                                                         Study nurses assessing mobility score blinded
  Prick 2013^13^            Not available   Not available                                                                         Not available
  Robertson 2014^40^        Not available   Not blinded                                                                           Trial investigators not blinded; outcome assessors blinded
  Shehata 2012^41^          Not available   Not available                                                                         Not available
  So-Osman 2010^45^         Not blinded     Surgeons/clinicians not blinded                                                       Assessor and study investigators blinded; study nurses not blinded
  Villanueuva 2013^6^       Not blinded     Not blinded                                                                           Not blinded
  Walsh 2013^10^            Blinded         Not blinded                                                                           Not available
  Webert 2008^44^           Not blinded     Not blinded                                                                           Study staff assessing bleeding and adjudication committee blinded
  Wu 2011^42^               Not available   Not available                                                                         Not available
  Zygun 2009^43^            Not available   Not available                                                                         Not available

![**Fig 2** Risk of bias summary for all included records](holl023030.f2_default){#fig2}

![**Fig 3** Risk of bias graph](holl023030.f3_default){#fig3}

Clinical outcomes
-----------------

### Mortality

Data on mortality were provided in 23 trials (8321 patients),[@ref4] [@ref5] [@ref6] [@ref7] [@ref8] [@ref9] [@ref10] [@ref11] [@ref12] [@ref15] [@ref28] [@ref29] [@ref30] [@ref32] [@ref33] [@ref36] [@ref37] [@ref40] [@ref41] [@ref42] [@ref43] [@ref73] but few trials followed the patients for 90 days or more.[@ref8] [@ref9] [@ref10] [@ref12] [@ref37] [@ref40]

A total of nine trials with 5707 randomised patients were included in the analysis of mortality in trials with lower risk of bias (fig 4[](#fig4){ref-type="fig"}),[@ref4] [@ref5] [@ref6] [@ref9] [@ref10] [@ref15] [@ref28] [@ref32] [@ref73] showing a relative risk of 0.86 (95% confidence interval 0.74 to 1.01; P=0.07; I^2^=27%) for restrictive versus liberal transfusion; the GRADE quality was judged to be low (table 3[](#tbl3){ref-type="table"}). The trial sequential analysis adjusted 95% confidence interval was 0.67 to 1.12 (fig 5[](#fig5){ref-type="fig"}).

![**Fig 4** Forest plot of mortality in lower risk of bias trials. Size of squares for risk ratio reflects weight of trial in pooled analysis. Horizontal bars represent 95% confidence intervals](holl023030.f4_default){#fig4}

###### 

  Summary of findings including GRADE quality assessment of evidence trials with lower risk of bias

  Variables                                                                No of participants (No of studies)   No with event/No in group (%)   Relative risk (95% CI)   Absolute effect                                                                                        Quality of the evidence (GRADE)               Quality assessment domains      
  ------------------------------------------------------------------------ ------------------------------------ ------------------------------- ------------------------ ------------------------------------------------------------------------------------------------------ --------------------------------------------- ------------------------------- ---------------------------------------------------------------------------------------------------------------------
  All cause mortality, longest follow-up, low risk of bias trials          5707 (9)                             445/2860 (15.6)                 495/2847 (17.4)          Random effects 0.86 (0.74 to 1.01); I^2^=27%; trial sequential analysis adjusted 95% CI 0.67 to 1.12   24 fewer per 1000 (from 45 fewer to 2 more)   Low; critical importance        Inconsistency: not serious\*; indirectness: not serious; imprecision: serious†; reporting bias: reporting bias‡
  Overall morbidity, lower risk of bias trials                             4517 (6)                             858/2261 (37.9)                 897/2256 (39.8)          Random effects 0.98 (0.85 to 1.12); I^2^=60%; trial sequential analysis adjusted 95% CI 0.81 to 1.19   8 fewer per 1000 (from 60 fewer to 48 more)   Very low; critical importance   Inconsistency: serious§; indirectness: not serious; imprecision: serious¶; reporting bias: reporting bias‡
  Fatal and non-fatal myocardial infarction in lower risk of bias trials   4730 (7)                             59/2369 (2.5)                   43/2361 (1.8)            Random effects 1.28 (0.66 to 2.49); I^2^=34%; trial sequential analysis adjusted 95% CI 0.40 to 4.13   6 more per 1000 (from 6 fewer to 27 more)     Very low; critical importance   Inconsistency: serious\*\*; indirectness: not serious; imprecision: very serious††; reporting bias: reporting bias‡

GRADE Working Group grades of evidence: low quality=further research is likely to have an important impact on confidence in estimate of effect and is likely to change the estimate; very low quality=very uncertain about the estimate.

Quality assessment domains: inconsistency=unexplained heterogeneity of results; indirectness=differences in population, intervention, comparator, and outcome measures; imprecision=relatively few patients and few events resulting in wide confidence intervals; reporting bias=publication bias is a systematic under-estimation or over-estimation of underlying beneficial or harmful effect owing to selective publication of trial results.

\*I^2^=27%, P=0.20for heterogeneity, overlap of confidence intervals.

†Anticipation of 15% relative risk reduction results in trial sequential analysis adjusted confidence intervals, including \>25% relative risk reduction or \>25% relative risk increase. However, \<15% relative risk reduction or relative risk increase may also be considered clinically relevant and these are apparently not excluded in any analyses.

‡Possibility for publication bias according to funnel plot owing to smaller trials showing benefit for restrictive transfusion strategy.

§I^2^=60%, P=0.03 for heterogeneity, overlap of confidence intervals.

¶Two trials showed no effect and appreciable harm with restrictive transfusion strategy.

\*\*I^2^=34%, P=0.11 for heterogeneity, variance in point estimates, from 0.25 to 2.97.

††6 of 7 trials showed no effect and appreciable harm with restrictive transfusion strategy.

![**Fig 5** Trial sequential analysis of nine trials with lower risk of bias reporting all cause mortality, control event proportion of 17.4%, diversity of 56%, α of 5%, power of 80%, and relative risk reduction of 15%. The required information size of 14 217 has not been reached and none of the boundaries for benefit, harm, or futility has been crossed, leaving the meta-analysis inconclusive of a 15% relative risk reduction. The trial sequential analysis adjusted 95% confidence interval for a relative risk of 0.86 is 0.67 to 1.12](holl023030.f5_default){#fig5}

Restrictive versus liberal transfusion strategies did not affect the relative risk of death (0.95, 95% confidence interval 0.81 to 1.11; P=0.52; I^2^=27%), including all trials despite risk of bias (fig 6[](#fig6){ref-type="fig"}); the GRADE quality was judged to be low (table 4[](#tbl4){ref-type="table"}). The trial sequential analysis adjusted 95% confidence interval was 0.74 to 1.21 (fig 7[](#fig7){ref-type="fig"}). Figure 8[](#fig8){ref-type="fig"} shows the results of meta-analysis on mortality in trials stratified by clinical setting.

![**Fig 6** Forest plot of mortality despite risk of bias. Size of squares for risk ratio reflects weight of trial in pooled analysis. Horizontal bars represent 95% confidence intervals](holl023030.f6_default){#fig6}

###### 

 Summary of findings including GRADE quality assessment of evidence, all trials

  Variables                                               No of Participants (studies)   No of events/No in group (%)   Relative risk (95% CI)   Absolute effect                                                                                         Quality of the evidence (GRADE)               Quality assessment domains      
  ------------------------------------------------------- ------------------------------ ------------------------------ ------------------------ ------------------------------------------------------------------------------------------------------- --------------------------------------------- ------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------
  All cause mortality, longest follow up, all trials      8321 (23)                      558/4167 (13.4)                586/4154 (14.1)          Random effects 0.95 (0.81 to 1.11); I^2^=27%); trial sequential analysis adjusted 95% CI 0.74 to 1.21   7 fewer per 1000 (from 27 fewer to 16 more)   Very low; critical importance   Risk of bias: very serious\*; inconsistency: not serious†; indirectness: not serious; imprecision: serious‡; reporting bias
  Overall morbidity, all trials                           5975 (12)                      1070/2982 (35.9)               1084/2993 (36.2)         1.06 (0.93 to 1.21); I^2^=58%                                                                           22 more per 1000 (from 25 fewer to 76 more)   Very low; critical importance   Risk of bias: very serious§; inconsistency: not serious¶; indirectness: not serious; imprecision: serious\*\*; reporting bias: reporting bias††
  Fatal and non-fatal myocardial infarction, all trials   6501 (16)                      145/3259 (4.4)                 137/3248 (4.2)           1.05 (0.82 to 1.36); I^2^=6%                                                                            2 more per 1000 (from 8 fewer to 15 more)     Low; critical importance        Risk of bias: very serious‡‡; inconsistency: not serious§§; indirectness: not serious; imprecision: serious¶¶; reporting bias: none

GRADE Working Group grades of evidence: low quality=further research is likely to have an important impact on confidence in estimate of effect and is likely to change the estimate; very low quality=very uncertain about the estimate.

Quality assessment domains: inconsistency=unexplained heterogeneity of results; indirectness=differences in population, intervention, comparator, and outcome measures; imprecision=relatively few patients and few events resulting in wide confidence intervals; reporting bias=publication bias is a systematic under-estimation or over-estimation of underlying beneficial or harmful effect owing to selective publication of trial results.

\*Overall 8 lower, 10 unclear, and 5 high risk of bias trials; limitations for more than one criterion; no blinded trials; assessor outcome not important for all cause mortality so only one level downgrade.

†I^2^=27% , P=0.12 for heterogeneity, overlap of confidence intervals.

‡Anticipation of 15% relative risk reduction results in trial sequential analysis adjusted confidence intervals including \>25% relative risk reduction or \>25% relative risk increase. However, \<15% relative risk reduction or relative risk increase may also be considered clinically relevant and these are apparently not excluded in any analyses.

§Overall 6 lower, 4 unclear and 2 high risk of bias trials; limitations for more than one criterion; possible assessment bias as all trials are unblended.

¶I^2^=58% and P=0.006 for heterogeneity.

\*\*Five of 12 trials showing no effect and appreciable harm with restrictive transfusion strategy.

††Possibility for publication bias according to funnel plot owing to smaller trials showing benefit for restrictive transfusion strategy.

‡‡Overall 5 lower, 5 unclear, and 5 high risk of bias trials.

§§ I^2^=11% and P=0.33 for heterogeneity.

¶¶10 trials showing no effect and appreciable benefit or harm with restrictive transfusion strategy.

![**Fig 7** Trial sequential analysis of 23 trials (despite risk of bias) reporting mortality, with control event proportion of 13.7%, diversity of 62%, α of 5%, power of 80%, and relative risk reduction of 15%. The required information size of 20 799 is far from reached and none of the boundaries for benefit, harm, or futility has been crossed, leaving the meta-analysis inconclusive of a 15% relative risk reduction. The trial sequential analysis adjusted 95% confidence interval for a relative risk of 0.95 is 0.74 to 1.21](holl023030.f7_default){#fig7}

![**Fig 8** Forest plot of mortality in trials stratified by clinical setting. Size of squares for risk ratio reflects weight of trial in pooled analysis. Horizontal bars represent 95% confidence intervals](holl023030.f8_default){#fig8}

### Overall morbidity

A total of six trials with lower risk of bias including 4517 patients were included in the meta-analysis of overall morbidity (fig 9[](#fig9){ref-type="fig"}).[@ref4] [@ref5] [@ref6] [@ref8] [@ref15] [@ref73] Overall morbidity did not differ between the restrictive and liberal transfusion strategies (relative risk 0.98, 95% confidence interval 0.85 to 1.12; P=0.75; I^2^=60%) and the trial sequential analysis adjusted 95% confidence interval was 0.81 to 1.19. Future trials are unlikely to show a 15% relative risk reduction in favour of restrictive or liberal strategies as the boundary for futility was crossed (fig 10[](#fig10){ref-type="fig"}). The GRADE quality of evidence was judged to be very low (table 3).

A total of 12 trials with 5975 randomised patients were included in the meta-analysis of overall morbidity regardless of risk of bias (relative risk 1.06, 95% confidence interval 0.93 to 1.21; P=0.36; I^2^=58%).[@ref4] [@ref5] [@ref6] [@ref7] [@ref8] [@ref15] [@ref35] [@ref37] [@ref39] [@ref41] [@ref46] [@ref73]

![**Fig 9** Forest plot of overall morbidity in low risk of bias trials. Size of squares for risk ratio reflects weight of trial in pooled analysis. Horizontal bars represent 95% confidence intervals](holl023030.f9_default){#fig9}

![**Fig 10** Trial sequential analysis of six trials reporting overall morbidity, a control event proportion of 40%, diversity of 75%, α of 5%, power of 80%, and relative risk reduction of 15%. The required information size of 7188 has not been reached, but the boundaries for futility are crossed, leaving out the possibility of a 15% relative risk reduction. The trial sequential analysis adjusted 95% confidence interval for a relative risk of 0.98 is 0.81 to 1.19](holl023030.f10_default){#fig10}

### Fatal or non-fatal myocardial infarction

Seven trials assessing fatal or non-fatal myocardial infarction including 4730 patients were defined as trials with lower risk of bias.[@ref4] [@ref5] [@ref9] [@ref10] [@ref15] [@ref28] [@ref73] Restrictive transfusion strategies were not associated with a relative risk reduction or relative risk increase in fatal or non-fatal myocardial infarction (relative risk 1.28, 95% confidence interval 0.66 to 2.49; P=0.46; I^2^=34%) (fig 11[](#fig11){ref-type="fig"}) and the trial sequential analysis adjusted 95% confidence interval was 0.40 to 4.31 (fig 12[](#fig12){ref-type="fig"}). The GRADE quality of evidence was judged to be very low (table 3). A total of 16 trials with 6501 randomised patients were included in the meta-analysis of fatal or non-fatal myocardial infarction regardless of risk of bias (1.05, 0.82 to 1.36; P=0.70; I^2^=6%); the GRADE quality of evidence was judged to be low (table 4).[@ref4] [@ref5] [@ref7] [@ref8] [@ref9] [@ref10] [@ref15] [@ref28] [@ref30] [@ref31] [@ref36] [@ref38] [@ref39] [@ref40] [@ref41] [@ref73]

![**Fig 11** Forest plot of myocardial infarctions in low risk of bias trials. Size of squares for risk ratio reflects weight of trial in pooled analysis. Horizontal bars represent 95% confidence intervals](holl023030.f11_default){#fig11}

![**Fig 12** Trial sequential analysis of seven trials reporting myocardial infarction, with a control event proportion of 1.8%, diversity of 62.3%, α of 5%, power of 80%, and relative risk reduction of 50%. The diversity adjusted required information size of 13 686 is far from reached and none of the boundaries for benefit, harm, or futility has been crossed, leaving the meta-analysis inconclusive of even a 50% relative risk reduction. The trial sequential analysis adjusted 95% confidence interval for a relative risk of 1.28 is 0.40 to 4.13](holl023030.f12_default){#fig12}

### Other adverse events

A total of eight trials defined as lower risk of bias with 5107 patients were included in the meta-analysis on infectious complications. Our analysis showed an association in favour of using a restrictive transfusion strategy (relative risk 0.73, 95% confidence interval 0.55 to 0.98, P=0.03, I^2^=53%) (see supplementary appendix 2).[@ref4] [@ref5] [@ref6] [@ref13] [@ref15] [@ref28] [@ref32] [@ref35] The inclusion of all 15 trials (7217 patients) regardless of risk of bias did not alter the result (0.79, 0.64 to 0.97, P=0.03, I^2^=40%).[@ref4] [@ref5] [@ref6] [@ref7] [@ref8] [@ref13] [@ref15] [@ref28] [@ref31] [@ref32] [@ref35] [@ref36] [@ref40] [@ref41] [@ref46] Our analysis showed no association of restrictive versus liberal transfusion with other adverse events (cardiac complications, renal failure, thromboembolic stroke or transitory ischaemic insult, or haemorrhage) (see supplementary appendices 3 and 4).

Number of patients and units transfused
---------------------------------------

A total of 24 trials with 8923 patients were included in the meta-analysis of the proportion of patients receiving red blood cells (relative risk 0.54, 95% confidence interval 0.47 to 0.63; P\<0.001; I^2^=95%), and a total of 12 trials with 4022 patients were included in the meta-analysis of the number of units transfused (mean difference −1.43, 95% confidence interval −2.01 to −0.86; P\<0.001; I^2^=96%) both showing lower numbers associated with restrictive versus liberal transfusion strategies (see supplementary appendices 5 and 6).

Discussion
==========

We did not find any association with mortality, overall morbidity, or myocardial infarction when comparing restrictive transfusion strategies with liberal transfusion strategies; however, the overall quality of evidence was low. We performed trial sequential analysis to account for sparse data and repetitive testing on accumulating data and found that the 95% confidence intervals of the point estimates widened and the results supported those obtained in the conventional meta-analyses. In our analysis of all cause mortality, the cumulative z curve did not cross any boundaries, with only 40% of the required information size being reached (5707 of 14 217 patients), indicating that further trials are needed to establish firm evidence. In our analysis of all trials, the trial sequential analysis indicated that it is unlikely that future trials will show overall harm with restrictive transfusion strategies. Regarding overall morbidity, we found no association with benefit or harm between groups, but the trial sequential analysis indicated it would be futile to obtain more trial data on this outcome. We found that the trial sequential analysis of pooled risk of fatal or non-fatal myocardial infarction was inconclusive, because only 26% of the required information size was obtained. Regarding infectious complications, our analysis indicated a possible association between a restrictive transfusion strategy and reduced rates of infection across the different clinical settings.

Relation to other reviews
-------------------------

Well conducted systematic reviews with meta-analysis on red blood cell transfusion have been published. A Cochrane review indicated that restrictive transfusion strategies were not associated with the rate of adverse events (that is, mortality, cardiac events, stroke, pneumonia, and thromboembolism) compared with liberal transfusion strategies. Restrictive transfusion strategies were associated with a reduction in hospital mortality (relative risk 0.77, 95% confidence interval 0.62 to 0.95) but not in 30 day mortality (0.85, 0.70 to 1.03).[@ref14]

A review was published in 2014 including 6936 patients from 19 trials assessing the impact of red blood cell transfusion.[@ref74] Pooled data from three trials (2364 patients) using restrictive haemoglobin transfusion triggers of 7 g/dL showed reductions in in-hospital mortality (relative risk 0.74, 95% confidence interval 0.60 to 0.92), total mortality (0.80, 0.65 to 0.98), rebleeding (0.64, 0.45 to 0.90), acute coronary syndrome (0.44, 0.22 to 0.89), pulmonary oedema (0.48, 0.33 to 0.72), and bacterial infections (0.86, 0.73 to 1.00) compared with liberal transfusion. In contrast, pooled data including trials with less restrictive transfusion thresholds did not show associations with any of the predefined outcomes.

A recent systematic review with meta-analysis included 18 randomised controlled trials reporting data on in-hospital infections.[@ref75] Restrictive transfusion strategies were associated with a reduced risk of infections among patients admitted to hospital compared with liberal transfusion strategies (0.88, 0.78 to 0.99). Our analysis showed comparable results, with a possibility of lowering the rate of infections using restrictive transfusion strategies. We also included data on non-healthcare associated infections, but our results may be influenced by multiple testing and sparse data.

We included data from the recent Transfusion Requirements In Septic Shock (TRISS) trial, which randomised 1005 patients with septic shock in the intensive care unit, in which there was no difference in mortality or morbidity with the use of pre-stored leucocyte reduced red blood cells at a transfusion trigger of 7 versus 9 g/dL.[@ref9] In accordance with the Cochrane review we did not find evidence of harm with the use of restrictive transfusion strategies compared with liberal transfusion strategies. However, our trial sequential analyses were inconclusive for the assessment of mortality and myocardial infarction owing to insufficient information sizes.

Strengths and limitations of this review
----------------------------------------

Applying Cochrane methodology is a major strength of this systematic review, comprising a prepublished protocol, a non-restricted up to date literature search, independent data extraction by at least two authors, and risk of bias assessment leading to GRADE evaluations of important outcomes. Trial sequential analysis was performed to explore the risk of random error as a result of sparse data and repetitive testing in order to increase the robustness of the meta-analyses and distinguish the current information size from the required information size.

Our systematic review also has limitations. The randomised controlled trials included in the primary analysis dealt with different indications for transfusion by randomising a variety of patient groups (for example, children and adults) in different clinical settings (for example, elective surgery and critical illness). Thus, the risk of introducing potentially important heterogeneity is imminent. To get a clinical applicable result, we excluded trials of neonates and infants with very low birth weight. None of the included trials was blinded, as this is not feasible. This may introduce both performance and detection bias. However, the primary outcome of all cause mortality is less prone to be influenced by lack of blinding.[@ref76] Transfusion triggers varied between trials, with some using a liberal transfusion threshold equal to the restrictive one in other trials, introducing clinical heterogeneity. Both clinical heterogeneity and inadequate follow-up increase the risk of type II error. Bias in the included trials, losses to follow-up, and incomplete reporting of outcome measures are additional limitations in this review. The definitions of overall morbidity and adverse events were heterogeneous and should be taken into account when interpreting these data. Finally, for some of the predefined outcomes, limited trial data could be included in the meta-analyses resulting in wide confidence intervals and less certain point estimates.

Unanswered questions
--------------------

Whether the overall use of red blood cells should be guided by a restrictive or a liberal transfusion strategy is still debatable. Patients with coronary artery disease, and in particular patients with ongoing cardiac ischaemia, might require a higher haemoglobin level to sustain oxygen delivery to the myocardial cells and to reduce the sympathetically mediated compensatory mechanisms of anaemia and reduce myocardial oxygen demand. However, red blood cell transfusion could worsen patient outcome as a result of an increased risk of circulatory overload and increased thrombogenicity with higher haematocrit levels. Results from the FOCUS trial showed no association with the primary composite outcome of morbidity and mortality 60 days postoperatively or the incidence of coronary syndrome when comparing two transfusion strategies (8 g/dL (or symptoms of anaemia) versus 10 g/dL).[@ref15] Two small randomised controlled trials evaluating a restrictive transfusion trigger of haemoglobin \<8 g/dL in patients with symptomatic coronary artery disease have been published[@ref8] [@ref73]; pooled data from these two trials randomising a total of 155 patients did not show an association between a restrictive transfusion strategy and cardiac events or mortality compared with a liberal transfusion strategy. A meta-analysis including observational studies on transfusion in patients with myocardial infarction indicates that the rates of subsequent myocardial infarction and all cause mortality may be associated with blood transfusions compared with standard supportive interventions, after adjustment for possible confounding variables.[@ref77] Large randomised controlled trials of restrictive compared with liberal transfusion are warranted in patients with myocardial infarction.

Patients with traumatic brain injury may require more liberal transfusion strategies to prevent secondary cerebral ischaemic insults because the injured brain may not compensate for decreased oxygen delivery associated with anaemia.[@ref78] One randomised controlled trial using a factorial design compared the effects of erythropoietin and two different haemoglobin thresholds for red blood cell transfusion (7 versus 10 g/dL) in 200 patients with a closed head injury and showed no difference in neurological outcome at six months.[@ref40] Also in patients with acute brain injury data from high quality randomised controlled trials are needed to guide transfusion practice.

Conclusions
-----------

In conventional meta-analyses restrictive transfusion strategies compared with liberal transfusion strategies were associated with a reduction in the number of red blood cells used and the number of patients being transfused but were not associated with benefit or harm regarding mortality, overall morbidity, and fatal or non-fatal myocardial infarction in various clinical settings. However, the required information sizes were not reached except for overall morbidity, where a 15% relative risk reduction or increase with restrictive transfusion strategies may be refuted. Analyses of all trials, regardless of risk of bias, showed similar findings. We found possible associations between restrictive transfusion strategies and a reduced number of infectious complications.

Restrictive transfusion strategies are safe in most clinical settings. Liberal transfusion strategies have not been shown to confer any benefit to patients but have the potential for harm.

### What is already known on this topic

1.  Red blood cells are commonly used in the treatment of haemorrhage and anaemia, but recent trials have shown potential harm with this intervention

2.  Recent meta-analysis indicates no harm with the use of a restrictive transfusion strategy

### What this study adds

1.  This review includes new data from five recently published randomised trials of restrictive versus liberal transfusion strategies and includes data from more than 9000 patients

2.  Pooled analyses did not show harm with restrictive transfusion strategies (no increased risk of mortality, overall morbidity, or acute myocardial infarction) but the number of units and number of patients transfused were reduced compared with liberal strategies

3.  Liberal strategies have possible associations with harm (risk of infectious complications)

4.  Further large trials with lower risk of bias are needed to establish firm evidence to guide transfusion in subgroups of patients
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